DNAAF2

Across TCGA pan-cancer cohorts, DNAAF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DNAAF2 data layer compared with 29 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DNAAF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAAF2 expression acts as an unfavorable survival marker.

BRCA, OV, and UCEC are the cancer types where DNAAF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.315	0.903	<.001	24	view →
OV	DFS	Median	All	0.168	0.541	.005	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
READ	OS	Median	All	0.652	0.828	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DNAAF2–BRCA (DFS)

Open the BRCA breakdown →